Call for Applications: Join the NMD4C Basic Science Trainee Committee (BSTC)
We are thrilled to announce that the applications are now open to join our Basic Science Trainee Committee (BSTC)
The Neuromuscular Disease Network for Canada (NMD4C) is inviting applications for our Basic Science Trainee Committee (BSTC) from trainees who are interested in contributing to national initiatives that support the neuromuscular research, clinical, and trainee communities.
We are currently seeking individuals who would like to be involved in one or more of the following areas:
- Podcast development and planning
- Social media and communications
- Developing a national database of standard operating procedures
- Website content creation and updates
- Workshop and training coordination
- Mentorship program development
Participation in the BSTC provides an opportunity to engage in national-level academic service, collaborate with colleagues across Canada, and gain experience in leadership, communication, and program development. Trainee members play a key role in shaping initiatives that directly support and enhance the neuromuscular research and training environment. We welcome applications from graduate students, research trainees, and postdoctoral fellows working in neuromuscular labs in Canada.
Interested trainees are invited to review the terms of reference and complete the application form below:
Extended Deadline: 23rd January, 2026
Read next...
New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada
We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.
Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy
NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.
Advancing AFC in Neuromuscular Medicine: Program Launch & September Workshop
The Royal College has approved National Training Standards for the AFC in Neuromuscular Medicine, creating a formal pathway to recognize enhanced competence with the DRCPSC credential. This designation establishes a national training standard, supports portable certification, and strengthens clinical capacity across Canada. PGME offices can now apply to offer accredited AFC programs, with a goal of five programs submitting applications by the end of 2026.